AI 聊天
正在載入 SOPH 的資料(首次造訪,需要幾秒鐘)。

SOPHiA GENETICS SA

SOPH · NasdaqGS · USD

6.49 -0.24 (-3.57%)

收盤價: Oct 19, 2026, 4:00 PM EDT

市值
$552.5M
下次財報日期
Nov 3, 2026

SOPHiA GENETICS SA(SOPH)股價、分析與資料

間隔:1D
正在載入K線和訊號…

內在價值

估值模型屬於 Pro 功能。登入或升級後可查看完整分析。

查看方案 →

分析師預測

股票預測 →

目標價

$7.00 – $14.00

中位數 $9.00 · 38.67% 上漲空間

12個月目標價 · 4 位分析師

分析師共識: 強購買

您正在查看免費總覽

建立免費帳戶,探索更多關於此標的的研究資料。

財務表現

查看財務 →
營收 (ttm)
$86.17M

正在載入...

最新財報

已通報較預期YoY 變更
營收$23.31Mn/a+27.22%
EPS-$0.20+$0.02+20.00%

下次財報

開盤前。

估計 · 升級 →

查看財報詳情 →

指標

買價
4.9
市值
552M
淨利(ttm)
-80.9M
0.95
-1.16
n/a
-12.98
P/B (ttm)
6.65
P/S (ttm)
6.41
財報日期
Nov 3, 2026
賣價
8.23
成交量
510,904
20 日平均成交量
587,926
開盤價
6.83
前收盤價
6.73
當日區間
6.42 - 6.95
52 週範圍
3.75 - 8.98
分析師
強購買
目標價
9 (38.67%)
股利
n/a
除息日
n/a

關於 SOPHiA GENETICS SA

查看公司資料 →
SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. It offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. The company has a partnership with Synnovis to bring blood-based cancer testing to patients in the United Kingdom and a collaboration with AstraZeneca to develop, validate, and deploy two companion diagnostics (CDx) supporting precision oncology therapies. The company was incorporated in 2011 and is based in Rolle, Switzerland. Health Information Services · Healthcare

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. It offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. The company has a partnership with Synnovis to bring blood-based cancer testing to patients in the United Kingdom and a collaboration with AstraZeneca to develop, validate, and deploy two companion diagnostics (CDx) supporting precision oncology therapies. The company was incorporated in 2011 and is based in Rolle, Switzerland.

類股 Healthcare
IPO 日期 Jul 23, 2021
員工 415
證券交易所 NasdaqGS
股票代號 SOPH